Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis.

@article{Fareed2004DifferentiationOL,
  title={Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis.},
  author={Jawed Fareed and Qing Ma and Michelle Florian and Jyothi Maddineni and Omer J. Iqbal and Debra A. Hoppensteadt and Rodger L. Bick},
  journal={Seminars in thrombosis and hemostasis},
  year={2004},
  volume={30 Suppl 1},
  pages={
          89-104
        }
}
Low-molecular-weight heparins (LMWHs) are now universally accepted as drugs of choice for postsurgical prophylaxis and treatment of deep vein thrombosis (DVT). Currently, these agents are also being developed for the treatment of various cardiovascular conditions. Because of manufacturing differences, each of the LMWHs exhibits distinct pharmacologic and biochemical profiles. The specific activity of these agents in anticoagulant assays ranges from 35 to 45 anti-IIa U/mg, whereas the activity… CONTINUE READING
Highly Cited
This paper has 27 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

Inhibition of Intrinsic Thrombin Generation

Drug target insights • 2006
View 7 Excerpts
Method Support
Highly Influenced

Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.

American journal of cardiovascular drugs : drugs, devices, and other interventions • 2012
View 1 Excerpt